The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Tue., May. 3, 2:11 PM

Slide #15. ADMA Biologics, Inc. Secondary Offering

Company: ADMA Biologics, Inc. (NASDAQ:ADMA)
Date announced: 4/27/2016
Shares Offered: 1,892,308
Date of Pricing: 4/28/2016
Price Per Share: $6.50
Secondary Offering Details: ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today that it intends to offer shares of its common stock in an underwritten public offering. The company expects to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 4/28 - ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the pricing of its previously announced underwritten public offering of 1,892,308 shares of common stock at a public offering price of $6.50 per share, resulting in gross proceeds of approximately $12.3 million. Members of management and the Board of Directors participated in excess of ten percent in the offering. The offering is expected to close on May 3, 2016, subject to the satisfaction of customary closing conditions. The company has also granted the underwriters a 30-day option to purchase up to 283,846 additional shares of common stock to cover over-allotments, if any.

ADMA Biologics is a biopharmaceutical company that develops and manufactures plasma-based biologics for the treatment and prevention of certain infectious diseases. Co.'s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. Co.'s main product candidate, RI-002, has been administered to patients in a Phase III clinical trial for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with polyclonal antibodies as well as antibodies targeted to respiratory syncytial virus.
Open the ADMA Page at The Online Investor »

Company Name:  ADMA Biologics Inc
Website:  www.admabiologics.com
Sector:  Biotechnology
Number of ETFs Holding ADMA:  2
Total Market Value Held by ETFs:  $35430
Total Market Capitalization:  $73.00M
% of Market Cap. Held by ETFs:  0.05%
 

Open the ADMA Page at The Online Investor (in a new window) »

May 3, 2016    2:11 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
98th percentile
(ranked higher than approx. 98% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.